Avid taps former GE exec as VP of marketing and sales
Philadelphia-based Avid Radiopharmaceuticals has named Christopher J. Bunting as its vice president of marketing and sales.
In his new role, Bunting will be responsible for the commercialization of F18-AV-45, the F18 compound in development for imaging amyloid plaque in the brain associated with Alzheimer's disease.
Bunting has more than 20 years of marketing and sales experience, most recently serving as global brand director for neurology at GE Healthcare in the United Kingdom. Prior to that, he led commercialization efforts at several pharmaceutical companies, including GlaxoSmithKline and AstraZeneca.
In his new role, Bunting will be responsible for the commercialization of F18-AV-45, the F18 compound in development for imaging amyloid plaque in the brain associated with Alzheimer's disease.
Bunting has more than 20 years of marketing and sales experience, most recently serving as global brand director for neurology at GE Healthcare in the United Kingdom. Prior to that, he led commercialization efforts at several pharmaceutical companies, including GlaxoSmithKline and AstraZeneca.